Abstract
The production and stability of recombinant retroviral vectors was examined at various temperatures. The two studied recombinant retroviral vectors, based on different packaging cell lines, exhibited a four-fold increased half-life at 32°C as compared to 37°C. Surprisingly, this increased stability at 32°C was only observed within a very narrow temperature window. At 30°C and 34°C, retroviral vector half-lives were quite similar to that at 37°C. Regardless of the vector half-life, retroviral vectors accumulated in the culture medium for a period of 48 h before an equilibrium was reached between retroviral vector production and decay. Maximal accumulated recombinant retroviral titers were five- to ten-fold increased after a medium incubation at 32°C as compared to 37°C. Furthermore, multiple cycles of freezing and thawing of retroviral vector supernatants hardly affected the recombinant retroviral vector titer, independent of the presence of serum. This knowledge on characteristics of recombinant retroviral vectors has practical implications for the manufacturing of these viruses for clinical gene therapy protocols.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaptein, L., Greijer, A., Valerio, D. et al. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Ther 4, 172–176 (1997). https://doi.org/10.1038/sj.gt.3300373
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300373
Keywords
This article is cited by
-
Viral vectors: from virology to transgene expression
British Journal of Pharmacology (2009)
-
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
Cancer Gene Therapy (2008)
-
Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles
Gene Therapy (2007)
-
A serum-free Vero production platform for a chimeric virus vaccine candidate
Cytotechnology (2006)
-
Retrovirus producer cell line metabolism: implications on viral productivity
Applied Microbiology and Biotechnology (2006)